Literature DB >> 21199451

Presynaptic dopamine in schizophrenia.

Nobumi Miyake1, Judy Thompson, Mette Skinbjerg, Anissa Abi-Dargham.   

Abstract

Presynaptic dopamine (DA) transmission has been measured in schizophrenia using different paradigms aimed at providing estimates of the integrity or the activity of the presynaptic dopaminergic neuron. RESEARCHERS HAVE MEASURED: (1) DA synthesis capacity with [(18) F]DOPA, a measure of the activity of dopa decarboxylase, (2) DA release with studies measuring the impact of a DA releasing stimulant challenge on the binding of a D(2) receptor radiotracer, (3) D(2) baseline occupancy by DA, a measure of baseline intrasynaptic DA, assessed by the changes in binding of D(2) radiotracer induced by DA depletion, and (4) the DA and the vesicular monoamine transporters, to assess the integrity of presynaptic terminals. The relationship between DA release and D(2) receptor occupancy at baseline by DA has also been assessed in the same patients. Overall, these different imaging modalities have converged to show a dysregulation of presynaptic dopaminergic activity in schizophrenia, leading to excessive DA release in the striatum, particularly in the projection to the associative striatum, an area of integration between cognitive and limbic cortical inputs. Excessive striatal presynaptic DA is linked to the emergence of acute psychotic symptoms and to their response to treatment in schizophrenia. Understanding the etiology of this dysregulation and its consequences on the rest of the circuitry is important for future drug development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21199451      PMCID: PMC6493810          DOI: 10.1111/j.1755-5949.2010.00230.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  67 in total

1.  Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography.

Authors:  A Laakso; H Vilkman; B Alakare; M Haaparanta; J Bergman; O Solin; J Peurasaari; V Räkköläinen; E Syvälahti; J Hietala
Journal:  Am J Psychiatry       Date:  2000-02       Impact factor: 18.112

2.  Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects.

Authors:  M Akil; C L Edgar; J N Pierri; S Casali; D A Lewis
Journal:  Biol Psychiatry       Date:  2000-03-01       Impact factor: 13.382

Review 3.  Increased dopamine transmission in schizophrenia: relationship to illness phases.

Authors:  M Laruelle; A Abi-Dargham; R Gil; L Kegeles; R Innis
Journal:  Biol Psychiatry       Date:  1999-07-01       Impact factor: 13.382

4.  Impaired recruitment of the hippocampus during conscious recollection in schizophrenia.

Authors:  S Heckers; S L Rauch; D Goff; C R Savage; D L Schacter; A J Fischman; N M Alpert
Journal:  Nat Neurosci       Date:  1998-08       Impact factor: 24.884

Review 5.  Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies.

Authors:  M Laruelle; A Abi-Dargham
Journal:  J Psychopharmacol       Date:  1999-12       Impact factor: 4.153

6.  FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa.

Authors:  W D Brown; M D Taylor; A D Roberts; T R Oakes; M J Schueller; J E Holden; L M Malischke; O T DeJesus; R J Nickles
Journal:  Neurology       Date:  1999-10-12       Impact factor: 9.910

Review 7.  Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review.

Authors:  M Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2000-03       Impact factor: 6.200

8.  Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET.

Authors:  L H Lindström; O Gefvert; G Hagberg; T Lundberg; M Bergström; P Hartvig; B Långström
Journal:  Biol Psychiatry       Date:  1999-09-01       Impact factor: 13.382

9.  Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects.

Authors:  M Akil; J N Pierri; R E Whitehead; C L Edgar; C Mohila; A R Sampson; D A Lewis
Journal:  Am J Psychiatry       Date:  1999-10       Impact factor: 18.112

10.  Brain receptors for antipsychotic drugs and dopamine: direct binding assays.

Authors:  P Seeman; M Chau-Wong; J Tedesco; K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  1975-11       Impact factor: 11.205

View more
  22 in total

1.  Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

2.  Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

3.  Neuregulin 1 signalling modulates mGluR1 function in mesencephalic dopaminergic neurons.

Authors:  A Ledonne; A Nobili; E C Latagliata; V Cavallucci; E Guatteo; S Puglisi-Allegra; M D'Amelio; N B Mercuri
Journal:  Mol Psychiatry       Date:  2014-09-30       Impact factor: 15.992

4.  Elevated Excitatory Input to the Nucleus Accumbens in Schizophrenia: A Postmortem Ultrastructural Study.

Authors:  Lesley A McCollum; Courtney K Walker; Joy K Roche; Rosalinda C Roberts
Journal:  Schizophr Bull       Date:  2015-03-27       Impact factor: 9.306

Review 5.  Stress and neurodevelopmental processes in the emergence of psychosis.

Authors:  C W Holtzman; H D Trotman; S M Goulding; A T Ryan; A N Macdonald; D I Shapiro; J L Brasfield; E F Walker
Journal:  Neuroscience       Date:  2013-01-05       Impact factor: 3.590

Review 6.  The prodrome and clinical risk for psychotic disorders.

Authors:  Sandra M Goulding; Carrie W Holtzman; Hanan D Trotman; Arthur T Ryan; Allison N Macdonald; Daniel I Shapiro; Joy L Brasfield; Elaine F Walker
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2013-06-18

Review 7.  Extracellular matrix abnormalities in schizophrenia.

Authors:  Sabina Berretta
Journal:  Neuropharmacology       Date:  2011-08-16       Impact factor: 5.250

8.  Uncovering the role of the nucleus accumbens in schizophrenia: A postmortem analysis of tyrosine hydroxylase and vesicular glutamate transporters.

Authors:  Lesley A McCollum; Rosalinda C Roberts
Journal:  Schizophr Res       Date:  2015-09-18       Impact factor: 4.939

Review 9.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

10.  Dopaminergic contributions to hippocampal pathophysiology in schizophrenia: a computational study.

Authors:  Peter J Siekmeier; David P vanMaanen
Journal:  Neuropsychopharmacology       Date:  2014-01-28       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.